Navigation Links
Experimental Vitiligo Treatment Shows Promise in Mice
Date:2/27/2013

WEDNESDAY, Feb. 27 (HealthDay News) -- A genetically modified protein could provide the first effective treatment for the skin condition vitiligo, a new study in mice suggests.

People with vitiligo have white patches on the face, hands and other parts of the body. Vitiligo is an autoimmune disorder in which the immune system becomes overactive and kills the pigment cells that give skin its color.

Researchers at the Loyola University Chicago Stritch School of Medicine developed a genetically modified protein that reversed vitiligo in mice and had similar effects on human skin tissue samples. Findings from animal studies do not always hold up in human trials, however.

A protein called HSP70i plays a major role in the autoimmune response that causes vitiligo. The researchers genetically modified an amino acid in the protein in order to create a mutant version of HSP70i. This version replaces normal HSP70i and reverses the autoimmune response that causes vitiligo, the study authors explained in a Loyola news release.

When the mutant HSP70i was given to mice with vitiligo, their salt-and-pepper fur turned black, giving them a normal appearance. The mutant protein had a similar effect on human skin samples, according to the study, published in the current issue of the journal Science Translational Medicine.

Researcher I. Caroline Le Poole, a professor in Loyola's Oncology Institute, and colleagues are seeking approval and funding to conduct a clinical trial of the modified protein in humans.

About 1 million Americans have vitiligo, which affects about one in 200 people worldwide. There are no long-term effective treatments for the condition. Current options include steroid creams, light therapy and skin grafts, but none of them can prevent vitiligo from progressing.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about vitiligo.

-- Robert Preidt

SOURCE: Loyola University Health System, news release, Feb. 27, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Harmful effects of bisphenol A proved experimentally
2. Experimental agent briefly eases depression rapidly in test
3. NIH-funded trial launched to assess experimental TB drug
4. Experimental graft-vs.-host disease treatment equivalent to standard care in Phase 3 trial
5. Experimental Antidepressant Appears Quick-Acting, Safe
6. More than a third of high-risk leukemia patients respond to an experimental new drug
7. Updated Clinical Results Show Experimental Agent Ibrutinib as Highly Active in CLL Patients
8. Experimental Insomnia Drug Shows Promise
9. Experimental Dengue Vaccine Shows Some Success
10. Standard chemotherapy provides higher survival rate than experimental in lung cancer patients
11. Cancer turns off important immune cells, complicating experimental vaccine therapies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vitiligo Treatment Shows Promise in Mice
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products ... six circular design challenges scheduled to run through early 2018. The challenges are presented ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SC&H Group, ... firm as a Principal in its IT Advisory Services practice . Rossi is ... months as market demand for strategic IT guidance grows, and the practice continues to ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... to visualize, detect, and eliminate cyber threats in real-time, today announced a strategic ... provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... families from two offices in Tyler, has announced the latest beneficiary of their ... Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 2017 According to a new market research report "Neural Network ... Software), Vertical, and Region - Global Forecast to 2021" published by MarketsandMarkets, the ... by 2021, at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... MarketsandMarkets Logo ...
(Date:1/17/2017)... and KANSAS CITY, Mo. ... Hospitals Neonatal Consortium (CHNC) has selected Velos and ... visionary data management and multicenter initiatives. ... comprised of 32 Neonatal Intensive Care Units at ... . The consortium provides a benchmark of ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
Breaking Medicine Technology: